Literature DB >> 7619759

Iodine seeds in the treatment of slowly proliferating tumours in the head and neck region.

M G Glaser1, M D Leslie, I Coles, A D Cheesman.   

Abstract

Locally recurrent/persistent disease is a major cause of morbidity and mortality in patients suffering from tumours arising in the head and neck region. Iodine-125, with its long half-life of 60 days, is particularly suited for the treatment of slowly proliferating tumours (e.g. adenoidcystic carcinomas) of this site. We report our experience with 18 patients using iodine-125 seeds, placed at the time of surgery in patients with such tumours. Eleven of the patients were treated for recurrent disease following previous radical treatment. Disease free survival was 89% at 2 years and 53% at 5 years after treatment. These results are encouraging in a group of patients in whom achieving and maintaining local control can be extremely difficult.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619759     DOI: 10.1016/s0936-6555(05)80811-8

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  7 in total

1.  125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.

Authors:  M-W Huang; L Zheng; S-M Liu; Y Shi; J Zhang; G-Y Yu; J-G Zhang
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

2.  Postoperative [¹²⁵I] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland: with associated risk factors.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Jie Zhang; Lei Zheng; Shu-Ming Liu; Ming-Wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-04-29       Impact factor: 3.621

3.  The incidence of radioepidermitis and the dose-response relationship in parotid gland cancer patients treated with 125I seed brachytherapy: incidence of radioepidermitis and the dose-response relationship.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Lei Zheng; Hong Gao; Jie Zhang; Shu-ming Liu; Ming-wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-09-09       Impact factor: 3.621

4.  Clinical application and accuracy assessment of imaging-based surgical navigation guided 125I interstitial brachytherapy in deep head and neck regions.

Authors:  Guohao Zhang; Zhiyuan Wu; Wenting Yu; Xiaoming Lyu; Wenjie Wu; Yi Fan; Yong Wang; Lei Zheng; Mingwei Huang; Yi Zhang; Chuanbin Guo; Jianguo Zhang
Journal:  J Radiat Res       Date:  2022-09-21       Impact factor: 2.438

5.  A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck.

Authors:  Ming-Wei Huang; Shu-Ming Liu; Lei Zheng; Yan Shi; Jie Zhang; Yan-Sheng Li; Guang-Yan Yu; Jian-Guo Zhang
Journal:  J Radiat Res       Date:  2012-08-01       Impact factor: 2.724

6.  The efficacy of iodine-125 permanent brachytherapy versus intensity-modulated radiation for inoperable salivary gland malignancies: study protocol of a randomised controlled trial.

Authors:  Shu-Ming Liu; Hai-Bo Wang; Yan Sun; Yan Shi; Jie Zhang; Ming-Wei Huang; Lei Zheng; Xiao-Ming Lv; Bao-Min Zheng; Kathleen H Reilly; Xiao-Yan Yan; Ping Ji; Yang-Feng Wu; Jian-Guo Zhang
Journal:  BMC Cancer       Date:  2016-03-07       Impact factor: 4.430

7.  Three-dimensional verification of ¹²⁵I seed stability after permanent implantation in the parotid gland and periparotid region.

Authors:  Yi Fan; Ming-Wei Huang; Lei Zheng; Yi-Jiao Zhao; Jian-Guo Zhang
Journal:  Radiat Oncol       Date:  2015-11-24       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.